The total return over the past 12 months is +5.21% vs. +16.94% for the S&P 500. So far it's up +1.68% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +5.21% | +7.74% | +7.56% | +10.90% | +24.24% | +13.36% |
| Total Return CAGR | +5.21% | +7.74% | +7.56% | +10.90% | +24.24% | +13.36% |
| Revenue CAGR | +34.42% | +26.33% | +26.74% | +71.88% | +31.94% | +18.80% |
| Net Income CAGR | +102.56% | +58.72% | +14.11% | N/A | +32.23% | N/A |
| EPS CAGR | +102.59% | +44.01% | +1.94% | N/A | N/A | N/A |
| Free Cash Flow CAGR | +63.72% | +46.12% | +28.69% | N/A | N/A | N/A |
| Operating Cash Flow CAGR | +58.31% | +44.72% | +28.24% | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Neurocrine Biosciences, Inc. (NBIX)
| Year | Start price | End price | NBIX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $141.83 | $144.21 | +1.68% | +14.51% | (12.83%) |
| 2025 | $136.50 | $141.83 | +3.90% | +17.72% | (13.82%) |
| 2024 | $131.76 | $136.50 | +3.60% | +24.89% | (21.29%) |
| 2023 | $119.44 | $131.76 | +10.31% | +26.19% | (15.88%) |
| 2022 | $85.17 | $119.44 | +40.24% | (18.17%) | +58.41% |
| 2021 | $95.85 | $85.17 | (11.14%) | +28.74% | (39.88%) |
| 2020 | $107.49 | $95.85 | (10.83%) | +18.37% | (29.20%) |
| 2019 | $71.41 | $107.49 | +50.53% | +31.22% | +19.31% |
| 2018 | $77.59 | $71.41 | (7.96%) | (4.56%) | (3.40%) |
| 2017 | $38.70 | $77.59 | +100.49% | +21.70% | +78.79% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
